EZH2 methyltransferase and H3K27 methylation in breast cancer

International Journal of Biological Sciences

Volumn 8, Issue 1, 2011, Pages 59-65

  Yoo, Kyung Hyun ^a   Hennighausen, Lothar ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

BRCA1; Breast cancer; EZH2; H3K27 methylation

Indexed keywords

EID: 82555173684     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.8.59     Document Type: Article

References (47)

1. Aagaard-Tillery KM, Suter MA, Harris A, et al. Epigenetics and reproduction and the developmental origins of health and dis-ease. Anim Reprod. 2010; 7: 103-16.
2. Peters AH, Kubicek S, Mechtler K, et al. Partitioning and plas-ticity of repressive histone methylation states in mammalian chromatin. Mol Cell. 2003; 12: 1577-89.
3. Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nature Rev Genet. 2007; 8: 9-22.
4. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011; 469: 343-9.
5. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002; 298: 1039-43.
6. Pasini D, Bracken AP, Jensen MR, et al. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J. 2004; 23: 4061-71.
7. Sewalt RGAB, van der Vlag J, Gunster MJ, et al. Characteriza-tion of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of dif-ferent mammalian polycomb-group protein complexes. Mol Cell Biol. 1998; 18: 3586-95.
8. Cao R, Zhang Y. SUZ12 is required for both the histone me-thyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell. 2004; 15: 57-67.
9. Shen X, Liu Y, Hsu YJ, et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintainingstem cell identity and executing pluripotency. Mol Cell. 2008; 32: 491-502.
10. Margueron R, Li G, Sarma K, et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell. 2008; 32: 503-18.
11. Wang L, Jin Q, Lee JE, et al. Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. Proc Natl Acad Sci U S A. 2010; 107: 7317-22.
12. Ezhkova E, Pasolli HA, Parker JS, et al. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell. 2009; 136: 1122-35.
13. Pereira JD, Sansom SN, Smith J, et al. Ezh2, the histone me-thyltransferase of PRC2, regulates the balance between self-renewal and differentiation in the cerebral cortex. Proc Natl Acad Sci U S A. 2010; 107: 15957-62.
14. Ezhkova E, Lien WH, Stokes N, et al. EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. Genes Dev. 2011; 25: 485-98.
15. Tachibana M, Sugimoto K, Fukushima T, et al. Set do-main-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem. 2001; 276: 25309-17.
16. Wu H, Chen X, Xiong J, et al. Histone methyltransferase G9a contributes to H3K27 methylation in vivo. Cell Res. 2011; 21: 365-7.
17. Hübner MR, Spector DL. Role of H3K27 Demethylases Jmjd3 and UTX in Transcriptional Regulation. Cold Spring Harb Symp Quant Biol. 2011; 75: 43-9.
18. Kunju LP, Cookingham C, Toy KA, et al. EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod Pathol. 2011; 24:786-93.
19. Gong Y, Huo L, Liu P, et al. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is pre-dictive of worse clinical outcome. Cancer. 2011; [Epub ahead of print]
20. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transfor-mation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003; 100: 11606-11.
21. Ding L, Erdmann C, Chinnaiyan AM, et al. Identification of EZH2 as a molecular marker for a precancerous state in mor-phologically normal breast tissues. Cancer Res. 2006; 66: 4095-9.
22. Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endo-metrium, prostate, and breast. J Clin Oncol. 2006; 24: 268-73.
23. Ren B, Cam H, Takahashi Y, et al. E2F integrates cell cycle pro-gression with DNA repair, replication, and G(2)/M check-points. Genes Dev. 2002; 16: 245-56.
24. Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003; 22: 5323-35.
25. Chang CJ, Yang JY, Xia W, et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell. 2011; 19: 86-100.
26. Fujii S, Tokita K, Wada N, et al. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene. 2011; [Epub ahead of print]
27. Fujii S, Ito K, Ito Y, et al. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem. 2008; 283: 17324-32.
28. Chi XZ, Yang JO, Lee KY, et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21WAF1/Cip1 expression in cooperation with transforming growth factor ß-activated SMAD. Mol Cell Biol. 2005; 25: 8097-107.
29. Du J, Li L, Ou Z, et al. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells. Breast Cancer Res Treat. 2011; [Epub ahead of print]
30. Yang X, Karuturi RK, Sun F, et al. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mecha-nisms in breast cancer cells. PLoS One. 2009; 4: e5011.
31. Cao Q, Yu J, Dhanasekaran SM, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 2008; 27: 7274-84.
32. Toll AD, Dasgupta A, Potoczek M, et al. Implications of en-hancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum Pathol. 2010; 41: 1205-9.
33. Rao ZY, Cai MY, Yang GF, et al. EZH2 supports ovarian carci-noma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis. 2010; 31:1576-83.
34. Puppe J, Drost R, Liu X, et al. BRCA1-deficient mammary tu-mor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res. 2009; 11: R63.
35. Phillips KA. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol. 2000; 18: 107S-12S.
36. Pejovic T, Koul A, Olsen D, et al. No BRCA1 germline mutation in a family with uterine papillary serous carcinoma: a case re-port. Eur J Gynaecol Oncol. 2001; 22: 336-8.
37. Gonzalez ME, Li X, Toy K, et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene. 2009; 28: 843-53.
38. Gonzalez ME, DuPrie ML, Krueger H, et al. Histone methyl-transferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Cancer Res. 2011; 71: 2360-70.
39. Puppe J, Drost R, Liu X, et al. BRCA1-deficient mammary tu-mor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res. 2009; 11: R63.
40. Boyer LA, Plath K, Zeitlinger J, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006; 441: 349-53.
41. Bracken AP, Dietrich N, Pasini D, et al. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transi-tions. Genes Dev. 2006; 20: 1123-36.
42. Lee TI, Jenner RG, Boyer LA, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. 2006; 125: 301-13.
43. Squazzo SL, O'Geen H, Komashko VM, et al. Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res. 2006; 16: 890-900.
44. Ku M, Koche RP, Rheinbay E, et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet. 2008; 4: e1000242.
45. Shukla V, Coumoul X, Cao L, et al. Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members. Cancer Res. 2006; 66: 7151-7.
46. Ito K, Lim AC, Salto-Tellez M, et al. RUNX3 attenuates be-ta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell. 2008; 14: 226-37.
47. Fiskus W, Wang Y, Sreekumar A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2009; 114: 2733-43.